Ubs Oconnor LLC Pliant Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

$1.72 Billion
Q2 2024

A detailed history of Ubs Oconnor LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 77,000 shares of PLRX stock, worth $860,090. This represents 0.05% of its overall portfolio holdings.

Number of Shares

77,000

Holding current value

$860,090

% of portfolio

0.05%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $814,660 - $1.2 Million	77,000 New	77,000 $827,000
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $196,665 - $380,730	10,500 New	10,500 $279,000

Others Institutions Holding PLRX

# of Institutions

158

Shares Held

63.8M

Call Options Held

481K

Put Options Held

105K

Deep Track Capital, LP Greenwich, CT

5.97M
Shares

$66.7 Million
2.11% of portfolio
Black Rock Inc. New York, NY

4.97M
Shares

$55.5 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.6M
Shares

$51.4 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

3.44M
Shares

$38.4 Million
0.0% of portfolio
First Light Asset Management, LLC Edina, MN

3.4M
Shares

$38 Million
3.33% of portfolio

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $544M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account